The European Commission has approved obicetrapib, as Ubeslo and as Evlarco (with ezetimibe), for adults with primary hypercholesterolaemia or mixed dyslipidaemia — what the companies call a first-in-class approval for …
The European Commission has approved obicetrapib, as Ubeslo and as Evlarco (with ezetimibe), for adults with primary hypercholesterolaemia or mixed dyslipidaemia — what the companies call a first-in-class approval for …
Anvisa cancelled Elevidys’s conditional registration on August 24 at Roche’s request, citing insufficient safety and efficacy data — ending Brazilian access to the country’s most expensive approved drug.
Mendoza becomes the first Argentine province to screen newborns for spinal muscular atrophy at birth, enabling pre-symptomatic treatment under a public-private accord with Novartis effective May 24, 2026.
You must be logged in to post a comment.